Archived AES Symposia 2008
Plenary II: Surgical Controversies in the Treatment of MTLE: How to Get There and What to Do When You Get There
Program Length: 1 hrs 30 min
With the finding that 70% of children with Dravet syndrome, or severe myoclonic epilepsy of infancy, have mutations of the sodium channel alpha 1 subunit gene, SCN1A, epilepsy genetics has moved into the clinical domain. The diagnostic finding of a SCN1A mutation associated with a Dravet phenotype has major implications for treatment, and prognostic and genetic counseling of this devastating disease. Translational research with the development of animal models of SCN1A mutations has afforded significant insights into the neurobiology of this disorder showing Dravet syndrome to be an “interneuronopathy.” This understanding impacts on optimization of therapy with the aim of improving developmental outcome.
- To diagnose Dravet Syndrome and related phenotypes in children and adults with refractory epilepsy
- To know when to order and how to interpret the results of SCN1A testing
- To better understand the pathophysiology of Dravet syndrome and its relationship to appropriate pharmacotherapy
- Use of early treatment, including adapted polytherapy and excluding specific antiepileptic drugs, in Dravet syndrome to improve epilepsy and cognitive outcome.
Neurologists, neurosurgeons, basic scientists and pharmacists
Co-Chairs: Robert E. Gross, M.D., Ph.D. and David W. Loring, Ph.D.
At Issue: Surgical Variables Affecting Outcome in MTLE
Robert E. Gross, M.D., Ph.D.
Memory Function and Quality-of-Life After Surgery for MTLE
John T. Langfitt, Ph.D.
Outcome after Tailored Lateral and Mesial Temporal Resections for MTLE
George A. Ojemann, M.D.
Outcome After Transcortical ("Selective") Amygdalohippocampectomy for MTLE
André Olivier, M.D., Ph.D.
Impact of Surgical Approach and Extent of Resection on Memory Outcome in MTLE
Christoph Helmstaedter, M.D., Ph.D.
Disclaimer: Opinions expressed with regard to unapproved uses of products are solely those of the faculty and are not endorsed by the American Epilepsy Society or any manufacturers of pharmaceuticals.